Johnson & Johnson news

   Watch this stock
Showing stories 11 - 20 of about 131   

Articles published

JNJ 100.22 +0.04 (0.04%)
price chart
Johnson & Johnson's Kim Kadlec Departs For AOL
Kim Kadlec, worldwide VP of the global marketing group at Johnson & Johnson Johnson & Johnson for the past eight years, is moving to AOL AOL to be head of relationship management, a new position.
Johnson & Johnson's Kim Kadlec Joining AOL  Adweek
AOL's Latest Executive Hiring: Johnson & Johnson's Kadlec  Wall Street Journal (blog)
Related articles »  
J&J beats forecasts, as it marches toward specialty care
Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.
Sales of Johnson & Johnson's New Hepatitis C Drug Soar  Wall Street Journal
J&J Raises Forecast as Demand for New Drugs Boosts Profit  Bloomberg
Related articles »  
Jury says Johnson & Johnson must pay $1.2M over defective vaginal-mesh ...
Johnson & Johnson was ordered by a Texas jury to pay $1.2 million to a woman who alleged one of the company's lines of vaginal-mesh implants to treat incontinence was defectively designed, in the first verdict against the company over those devices.
$1.2 million to woman injured by J&J mesh implant  Philadelphia Business Journal (blog)
Texas Jury Hearing Transvaginal Mesh Lawsuit Levies $1.2 Million Judgment ...  Virtual-Strategy Magazine (press release)
Related articles »  
Warfarin's Loss is Johnson & Johnson's Gain
The second wave of this treatment tidal shift came with the 2011 approval of Johnson & Johnson's (NYSE: JNJ ) Xarelto, a Factor Xa drug that works in a completely new way.
Stock Market Today: Coca-Cola and Johnson & Johnson Boost the Dow
Johnson & Johnson today beat Wall Street forecasts for its first-quarter results on both the top and bottom lines. Sales improved by 3.5% to $18.1 billion while profit jumped by 7% to $1.54 a share.
Stocks to Watch: Coca-Cola, Johnson & Johnson, Zebra Technologies  Wall Street Journal (blog)
US stocks open higher, extending modest rally; Johnson & Johnson reports ...  Newser
Related articles »  
Johnson & Johnson's Headache-Fixing Earnings, Mattel's Un-Fun Earnings, and ...
Sure, its business may not be as sexy as Google's, but Johnson & Johnson (NYSE: JNJ ) is our stock winner of the week after an earnings report that got rid of investors' headaches.
Johnson & Johnson Is A Healthy Stock In A Volatile Market
With many momentum stocks appearing to peter out, investors could do a lot worse than investing in a blue chip stock like Johnson & Johnson (JNJ) when it's valued at such a cheap price. Diversification & Consistent Profits. JNJ sells a massive variety ...
Related articles »  
Johnson & Johnson Reports Higher Q1 Earnings; Beats Estimates; Gives FY ...
Before the opening bell on Tuesday, Johnson & Johnson (JNJ ) reported its first quarter earnings, posting higher Q1 revenues over last year and upping its guidance for FY2014.
How Big Is the Threat to This Johnson & Johnson Blockbuster?
Johnson & Johnson (NYSE: JNJ ) has been one of the most successful big drug companies over the past three years. Despite an industry-wide sales drag caused by patent expiration on top-selling drugs, Johnson has skirted the headwind thanks to a wave of ...
Motley Fool: Put Johnson & Johnson in long-term portfolio
Big blue-chip companies might not grow rapidly, but they can offer more stability than smaller counterparts, and they often pay dividends, too.